Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 22,000 shares, a drop of 18.2% from the November 15th total of 26,900 shares. Based on an average trading volume of 1,240,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.7% of the shares of the company are short sold.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MNPR shares. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 11th.

Monopar Therapeutics Trading Up 4.7 %

Shares of MNPR stock traded up $1.13 on Friday, reaching $25.38. The company’s stock had a trading volume of 47,461 shares, compared to its average volume of 638,553. The stock’s fifty day simple moving average is $15.94 and its 200-day simple moving average is $7.83. Monopar Therapeutics has a 1 year low of $1.40 and a 1 year high of $38.50. The company has a market capitalization of $133.96 million, a price-to-earnings ratio of -12.88 and a beta of 1.23.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. Equities research analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of Monopar Therapeutics stock in a transaction dated Monday, October 28th. The shares were purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at approximately $25,187.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.